Table 1.
Patient characteristics
| Control | Experimental | ||
|---|---|---|---|
| Patients analyzed | 31 | 29 | |
| Gender | Male | 15 | 15 |
| Female | 16 | 14 | |
| Age (mean, range) | [years] | 59 (39–73) | 59 (45–77) |
| WHO-PS | 0 | 20 (65 %) | 10 (34 %) |
| 1 | 10 (32 %) | 18 (62 %) | |
| 2 | 1 (3 %) | 1 (3 %) | |
| Smoker | Current | 13 (42 %) | 14 (48 %) |
| Ex | 14 (45 %) | 12 (41 %) | |
| Never | 4 (13 %) | 3 (11 %) | |
| Histology | Adeno | 27 (86 %) | 24 (83 %) |
| Large cell | 2 (7 %) | 1 (3 %) | |
| Other | 2 (7 %) | 4 (14 %) | |
| Survival (median, range) | PFS [months] | 7 (3–25) | 4 (1–11) |
| OS [months] | 13 (4–33) | 9 (2–29) | |
| RECIST response (week 6) | Complete response | 0 (0 %) | 0 (0 %) |
| Partial response | 9 (29 %) | 5 (17 %) | |
| Stable disease | 20 (65 %) | 17 (59 %) | |
| Progressive disease | 2 (6 %) | 7 (24 %) | |
| Baseline (mean, range) | CT diameter [cm] | 6.8 (2.5–12.1) | 6.7 (2.4–16.4) |
| CT volume [cm3] | 101.5 (4.4–474.5) | 89.8 (3.0–468.8) | |
| SUVmax | 13.5 (3.4–28.9) | 14.5 (3.6–44.6) | |
| SUVmean | 5.7 (2.5–11.8) | 6.2 (2.1–22.3) | |
| SUVpeak | 11.0 (3.1–25.3) | 12.1 (2.6–37.9) | |
| TLG [SUV*cm3] | 655.0 (23.4–4288.8) | 638.4 (8.2–3467.2) | |
WHO-PS World Health Organization performance status, PFS progression-free survival, OS overall survival, RECIST response evaluation criteria in solid tumors, SUV standardized uptake value, TLG total lesion glycolysis